聚焦超声手术与宫腔镜切除术治疗黏膜下子宫肌瘤(FIGO 2型)的比较
前瞻性队列研究比较聚焦超声手术(FUS)与宫腔镜宫颈管内肌瘤切除术(TCRM)治疗FIGO 2型黏膜下子宫肌瘤的疗效。共81例患者,FUS组39例、TCRM组42例,两组术后3、6、12个月UFS评分均显著下降、QoL评分均显著升高(p<0.05),FUS组住院时间和恢复工作时间均显著短于TCRM组(p<0.05),两组均无重大并发症。
要点
- FIGO 2型黏膜下肌瘤直径≤5 cm时,FUS与TCRM均可耐受且有效,症状和生活质量均显著改善。
- FUS组术后住院时间2.56±0.98天,显著短于TCRM组的3.31±0.60天(p<0.05)。
- FUS组恢复工作时间3.14±0.83天,显著短于TCRM组的6.09±0.9天(p<0.05)。
诊断标准与关键数值
- FUS组肌瘤平均直径3.8±0.9 cm(范围2.0-5.0 cm),TCRM组3.5±0.8 cm(范围2.0-4.8 cm)。
- 两组术后3、6、12个月UFS评分均较基线显著下降、QoL评分均较基线显著升高(p<0.05)。
- 两组均无重大并发症发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The aim of the study described here was to compare the effectiveness of focused ultrasound surgery (FUS), which uses high-intensity focused ultrasound to perform tissue ablation, with that of hysteroscopic transcervical resection of myoma (TCRM) for the treatment of type 2 submucosal fibroids. A prospective cohort study was performed in patients who underwent FUS or TCRM from January 2012 to December 2014. Uterine Fibroid Symptom (UFS) and Quality of Life (QoL) questionnaires were used to measure fibroid-related symptoms and quality of life before and at 3, 6 and 12 mo after treatment. Technical results, adverse events and post-operative recovery times of both groups were also compared. A total of 81 patients with at least one type 2 submucosal fibroid were enrolled. The mean diameter of type 2 submucosal fibroids was 3.8 ± 0.9 cm (range: 2.0-5.0 cm) for 39 patients in the FUS group and 3.5 ± 0.8 cm (range: 2.0-4.8 cm) for the 42 patients enrolled in the TCRM group. No major complication occurred in any patients for either treatment. In both groups, the UFS score decreased significantly and the QoL score increased significantly from baseline successively at 3, 6 and 12 mo post-treatment (p < 0.05). Time spent in hospital post-treatment was significantly shorter (2.56 ± 0.98 d) for the FUS group compared with the TCRM group (3.31 ± 0.60 d) (p < 0.05). Time to return to work after treatment was also significantly shorter for the FUS group (3.14 ± 0.83 d) than for the TCRM group (6.09 ± 0.9 d) (p < 0.05). FUS and TCRM are both tolerable and effective treatments with significant improvement of symptom and quality of life for patients with type 2 submucosal fibroids ≤5 cm in diameter.
引用
- Hu L, Zhao JS, Xing C, et al. Comparison of Focused Ultrasound Surgery and Hysteroscopic Resection for Treatment of Submucosal Uterine Fibroids (FIGO Type 2). Ultrasound Med Biol. 2020. PMID: 32359807. doi:10.1016/j.ultrasmedbio.2020.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。